pSivida raises $15m for BioSilicon development
This article was originally published in Clinica
Australian bio-nanotech firm pSivida has secured an additional $15m funding, following the sale of subordinated convertible debts to a New York-based institutional investor. The debts will mature three years from the date of closing, expected to be in mid-November, and are convertible into American Depository Receipts at an initial conversion price of $7.10. Perth-based pSivida says it will use the proceeds from the note sale for the expanded development of its proprietary product, BioSilicon. The company recently acquired Control Delivery Systems (CDS), a Boston, Massachusetts-based ophthalmic drug delivery company, and is planning to incorporate BioSilicon with CDS' Aeon technology.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.